NASDAQ
26.86USD
-0.62 (-2.26%)
We have scored 13 news catalysts on Zymeworks Inc. (ZYME) over the past 12 months. The biggest single-day move next to one of them came May 9, 2026, when ZYME closed −10.2%: “Zymeworks Q1 Earnings Call Highlights”. Coverage across the window leans positive (average ticker sentiment +0.51). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2B
P/E
—
EPS
—
Beta
1.19
52W range
15.81-31.34
Day range
26.68–27.55
Open
27.45
Prev close
27.48
Volume
117.4K
Avg volume
650.7K
Dividend
0.00
IPO
2017-04-28
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Zymeworks Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Zymeworks Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for ZYME: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
